Results 191 to 200 of about 35,110 (216)

Mechanisms of acquired resistance to cetuximab: role of interleukin-1

2016
Cetuximab (CX) is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is commonly utilized to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, clinicians often observe a residual disease, with a population of cells surviving the treatment and eventually enabling CX resistance.
Valerio Gelfo, Michela Pucci, Moshit Lindzen, Maria Teresa Rodia, Rossella Solmi, Massimiliano Bonafè, Elisabetta Caramelli, Yosef Yarden, Mattia Lauriola.   +8 more
openaire   +4 more sources

Abstract 2562: Role of MET signaling in cetuximab resistance and generation of an imaging biomarker to identify MET-driven cetuximab resistance in colorectal cancer

Cancer Research, 2023
Abstract We have previously identified that in the absence of MET amplification or mutation, RTK hyperphosphorylation, indicative of its active state, may contribute to resistance to the EGFR-directed therapeutic, cetuximab in colorectal cancer (CRC).
Vivian T. Jones, Ramona Graves-Deal, KyuOK Jeon, Adam J. Rosenberg, Zheng Cao, Galina T. Bogatcheva, Sarah J. Harmych, James N. Higginbotham, Kwangho Kim, James W. Janetka, Gary A. Sulikowski, Bhuminder Singh   +11 more
openaire   +1 more source

Differential escape mechanisms in cetuximab-resistant head and neck cancer cells

Biochemical and Biophysical Research Communications, 2019
Acquired cetuximab resistance is a challenge for oncologists treating advanced head and neck carcinoma (HNC). While intrinsic cetuximab resistance mechanism in colorectal cancer is known, resistance in HNC is unclear. We established two different cetuximab resistant HNC cell lines by culturing epidermal growth factor (EGFR) expressing UM-SCC-1 and UM ...
Christopher D. Willey, Joshua C. Anderson, Hoa Q. Trummell, Faris Naji, Rik de Wijn, Eddy S. Yang, Markus Bredel, Nanda K. Thudi, James A. Bonner   +8 more
openaire   +2 more sources

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

Cancer Letters, 2014
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that "resistant" cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of ...
Boeckx, Carolien, op de Beeck, Ken, Wouters, An, Deschoolmeester, Vanessa, Limame, Ridha, Zwaenepoel, Karen, Specenier, Pol, Pauwels, Patrick, Vermorken, Jan Baptist, Peeters, Marc, Van Camp, Guy, Baay, Marc, Lardon, Filip   +12 more
openaire   +3 more sources

Abstract 3733: Heregulin as a novel resistant factor for cetuximab

Cancer Research, 2010
Abstract Background Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). Patients with CRC with wild type KRAS have significant tumor regressions with cetuximab. However cancers ultimately acquire resistance. The mechanisms of these are still unknown.
Kimio Yonesaka, Isamu Okamoto, Taroh Satoh, Kohji Takeda, Minoru Takada, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Janne, Kazuhiko Nakagawa   +8 more
openaire   +1 more source

Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.

Anticancer research, 2012
Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line. The reason behind this suggestion is unclear.The
Lars, Ekblad, Anders, Johnsson
openaire   +1 more source

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

New England Journal of Medicine, 2006
James A Bonner, Paul M Harari, Dong M Shin   +2 more
exaly  

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

New England Journal of Medicine, 2004
David Cunningham, Salvatore Siena, Armando Santoro   +2 more
exaly  

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

New England Journal of Medicine, 2008
Ricard Mesia, Fernando Rivera, Ihor O Vynnychenko   +2 more
exaly  

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Lancet, The, 2019
Avraham Eisbruch, Paul M Harari, Erich M Sturgis   +2 more
exaly